Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancer

被引:0
|
作者
Jiang, Yupeng [1 ]
Liu, Yuyao [2 ]
Huang, Hong [3 ]
Zhao, Tiantian [1 ]
Zhao, Zengyi [1 ]
Gao, Yawen [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha 410011, Hunan, Peoples R China
[2] Univ South China, Affiliated Changsha Cent Hosp, Hengyang Med Sch, Dept Oncol, Changsha 410004, Peoples R China
[3] Guilin Med Univ, Guilin 541000, Peoples R China
关键词
RAS mutation; High microsatellite instability; Deficient mismatch repair; Colorectal cancer; Tumor microenvironment; TUMOR-INFILTRATING LYMPHOCYTES; MISMATCH REPAIR-DEFICIENT; DENDRITIC CELLS; MICROSATELLITE INSTABILITY; KRAS MUTATION; E-SELECTIN; OPEN-LABEL; MICROENVIRONMENT; PEMBROLIZUMAB; CHEMOTHERAPY;
D O I
10.1007/s00262-024-03926-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeMicrosatellite high instability/deficient mismatch repair (MSI-H/dMMR) colorectal cancer (CRC) has an active tumor microenvironment, rendering it more sensitive to immune checkpoint inhibitors. Given that studies involving patients with MSI-H colorectal cancer with RAS mutations are scarce, we explored the effect of RAS mutations on the TME in patients with MSI-H/dMMR cancer and identified potential prognostic factors.MethodsSeventy-five patients diagnosed with MSI-H/dMMR colorectal cancer were retrospectively enrolled and divided into RAS-mutant and -wild-type groups. The expression levels of CD11c+ dendritic cells, CD4+ T cells, CD8+ T cells, and regulatory T cell (Treg) markers were detected, and prognostic factors were analyzed.ResultsRAS-mutant MSI-H colorectal patients were more likely to have: (1) higher platelet values; (2) shorter disease-free survival (DFS); (3) lower infiltrated numbers of CD11c+ dendritic cells, CD4+ T lymphocytes, and CD8+ T lymphocytes, and higher infiltrated numbers of Foxp3+ Treg cells. In MSI-H/dMMR CRC patients: (1) the high CD11c + , CD4 +, and CD8 + cells infiltration group had longer DFS than the low-infiltration group, and Foxp3 + cells infiltration was not significantly correlated with DFS; (2) the RAS mutation status, number of CD11c+ cells infiltrated, and carbohydrate antigen 19-9 (CA19-9) level were the potential prognostic factors.ConclusionRAS mutations in patients with MSI-H/dMMR CRC may reduce the infiltration of CD11c+ dendritic cells, CD4+ T cells, and CD8+ T cells, and increase the infiltration of Foxp3+ Treg cells to affect the tumor microenvironment of patients. RAS gene status, CD11c + cells infiltration, and CA19-9 level were potential prognostic factors for MSI-H/dMMR CRC.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment
    Song, Yunfeng
    Gu, Ye
    Hu, Xiang
    Wang, Mengfei
    He, Qizhi
    Li, Yiran
    ONCOTARGETS AND THERAPY, 2021, 14 : 4485 - 4497
  • [32] An interpretable deep learning model for identifying the morphological characteristics of dMMR/MSI-H gastric cancer
    Zheng, Xueyi
    Jing, Bingzhong
    Zhao, Zihan
    Wang, Ruixuan
    Zhang, Xinke
    Chen, Haohua
    Wu, Shuyang
    Sun, Yan
    Zhang, Jiangyu
    Wu, Hongmei
    Huang, Dan
    Zhu, Wenbiao
    Chen, Jianning
    Cao, Qinghua
    Zeng, Hong
    Duan, Jinling
    Luo, Yuanliang
    Li, Zhicheng
    Lin, Wuhao
    Nie, Runcong
    Deng, Yishu
    Yun, Jingping
    Li, Chaofeng
    Xie, Dan
    Cai, Muyan
    Nie, Runcong
    ISCIENCE, 2024, 27 (03)
  • [33] MSI-H/dMMR and cancer immunotherapy: current state and future implications
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Gadaleta-Caldarola, Gennaro
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (06): : 345 - 347
  • [34] Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
    Zhang, Xuan
    Wu, Tao
    Cai, Xinyi
    Dong, Jianhua
    Xia, Cuifeng
    Zhou, Yongchun
    Ding, Rong
    Yang, Renfang
    Tan, Jing
    Zhang, Lijuan
    Zhang, Ya
    Wang, Yuqin
    Dong, Chao
    Li, Yunfeng
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [35] Clinical outcomes of immune checkpoint inhibitor (ICI) therapy among Veterans Affairs patients with colorectal cancer and discordant dMMR/MSI-H status.
    Isaacs, James
    Guo, Aixia
    Vashistha, Vishal
    Katsoulakis, Evangelia
    Boswell, Elizabeth
    Strickler, John H.
    Ahmed, Sara
    Kelley, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] COMPANION DIAGNOSTIC ASSAYS FOR PEMBROLIZUMAB IN PATIENTS WITH MSI-H/DMMR TUMORS
    Marabelle, Aurelien
    Cesario, Jeff
    Lang, Lixin
    Aurora-Garg, Deepti
    Mathur, Siddhartha Krishan
    Levitan, Diane
    Card, Deb
    Jin, Fan
    Adelberg, David
    Andre, Thierry
    Wehn, Amy
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A569 - A569
  • [37] Real-world experience of immune checkpoint inhibitors in MSI-H/dMMR metastatic colorectal cancer in a tertiary cancer center in Saudi Arabia
    Ajina, R.
    Alhareeri, A.
    Philip, W.
    Alsekait, N.
    Alarifi, N.
    Alismail, H.
    Alshieban, S.
    Almuzzaini, B.
    Alshammari, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S117 - S117
  • [38] Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
    Liu, Fangcen
    Zhong, Fangfang
    Wu, Huan
    Che, Keying
    Shi, Jiaochun
    Wu, Nandie
    Fu, Yao
    Wang, Yue
    Hu, Jing
    Qian, Xiaoping
    Fan, Xiangshan
    Wang, Weifeng
    Wei, Jia
    ONCOLOGIST, 2023, : e136 - e144
  • [39] Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2025, 22 (02) : 79 - 79
  • [40] Immunotherapy outcomes in dMMR/MSI-H and/or TMB-H metastatic colorectal cancer (CRC) with peritoneal metastases (PM).
    Mosalem, Osama M.
    Elhariri, Ahmed
    Wiest, Nathaniel Edward
    Kamatham, Saivaishnavi
    Abdel-Razeq, Nayef Hikmat
    Jones, Jeremy Clifton
    Sonbol, Mohamad B.
    Jin, Zhaohui
    Babiker, Hani M.
    Bekaii-Saab, Tanios S.
    Majeed, Umair
    Starr, Jason S.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 163 - 163